Delivery Order SPE2DB25D3020-SPE2DB25FWKMN
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30, with a contract ceiling value of $5,097.35. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and represents a non-set-aside competitive award. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This competitive award, valued at approximately $45K, represents a firm fixed-price delivery order with an ultimate completion date of August 21, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package, valued at $4,022.60. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is expected to reach completion by September 9, 2025. The delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion prime vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package at a ceiling value of $1,333.77. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This non-set-aside, firm fixed-price delivery order carries a ceiling value of $3,773.74 and is scheduled for completion by September 4, 2025. The contract leverages AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units, with a contract ceiling value of $10,763.89. This firm fixed-price delivery order, which reaches ultimate completion on August 14, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30, valued at $29,475.49 under a firm fixed-price contract. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The award carries no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Dapagliflozin 10 mg tablets in a 30-count package, valued at $1,036.29. This firm fixed-price delivery order, with an ultimate completion date of August 21, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dapagliflozin 10 mg tablets (30-count package) under a firm fixed-price contract valued at $1,722.16. This is a non-set-aside competitive award with an ultimate completion date of August 4, 2025, with performance to take place at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, for the supply of Dapagliflozin 10 mg tablets in quantities of 30 units. This firm fixed price delivery order, valued at $26,330.84, was competitively awarded without set-aside restrictions and carries an ultimate completion date of July 31, 2025. The award represents a child contract issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA...
- SPE2DB25D3020Indefinite Delivery Contract
- SPE2DB25D3020-SPE2DB25FWKMNDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dapagliflozin 10 mg tablets in quantities of 30, with a contract value of $4,353.54 and completion deadline of September 10, 2025. This non-set-aside, firm fixed-price delivery order represents a continuation of AmerisourceBergen's substantial role as a pharmaceutical supplier to the federal government. The award is executed under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to meet competitive procurement requirements across diverse therapeutic domains, including diabetes medications, neurological treatments, pain management pharmaceuticals, and specialized medical supplies. This delivery order for Dapagliflozin, a diabetes medication, exemplifies the company's ongoing role in supplying essential pharmaceutical commodities to support Defense Health Agency operations and other government healthcare systems through the DLA's flexible and comprehensive contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 9/9/25 |